Welcome to our dedicated page for Orchestra BioMed Holdings news (Ticker: OBIO), a resource for investors and traders seeking the latest updates and insights on Orchestra BioMed Holdings stock.
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) generates news primarily around its cardiovascular device programs, strategic partnerships and capital markets activity. The company describes itself as a biomedical innovation platform that advances high-impact technologies to patients through collaborations and risk-reward sharing agreements with global medical device companies, which often leads to announcements of new agreements, trial milestones and financial transactions.
News coverage for Orchestra BioMed frequently highlights progress in its two flagship product candidates: Atrioventricular Interval Modulation (AVIM) Therapy for hypertension and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for atherosclerotic artery disease. Investors can expect updates on pivotal clinical trials such as the BACKBEAT global study for AVIM Therapy and the Virtue Trial, a U.S. IDE pivotal trial comparing Virtue SAB to a commercially available paclitaxel-coated balloon in coronary in-stent restenosis.
The company’s releases also detail strategic collaborations and rights agreements, including its partnership with Medtronic for AVIM Therapy and a right of first refusal arrangement with Terumo related to Virtue SAB for coronary artery disease. Additional news items describe revenue participation and financing agreements with partners such as Ligand Pharmaceuticals, as well as public offerings, private placements and preferred stock issuances that support its clinical programs.
On this OBIO news page, readers can review company press releases, third-party announcements referencing Orchestra BioMed and regulatory-related communications. Topics typically include clinical data presentations, conference participation, updates on FDA Breakthrough Device Designation status for AVIM Therapy and Virtue SAB, and disclosures of material agreements filed via Form 8-K. Investors and researchers who follow developments in device-based hypertension therapy and drug-delivery balloons for coronary and peripheral artery disease may find this news feed particularly relevant.
Vivasure Medical has received CE Mark approval for its PerQseal Elite vascular closure system, a pioneering fully absorbable and sutureless large-bore vessel closure device. The product will be launched in select European markets this summer.
The PerQseal Elite system is specifically designed for closure following large-bore percutaneous cardiovascular procedures like TAVR and EVAR. It stands out as the first fully bioresorbable device in this category and requires no pre-procedure steps, offering improved procedural efficiency.
The device is placed from inside the vessel, providing simpler and more controlled deployment compared to conventional techniques. It restores the vessel to its natural state without leaving behind materials such as collagen, metal implants, or sutures.
Orchestra BioMed (Nasdaq: OBIO) has received FDA Breakthrough Device Designation (BDD) for its atrioventricular interval modulation (AVIM) therapy. The designation applies to an estimated 7.7 million U.S. patients with uncontrolled hypertension and increased cardiovascular risk.
The AVIM therapy, delivered through an implantable pacemaker system, is designed for patients with preserved left ventricular systolic function and uncontrolled hypertension, despite using anti-hypertensive medications. The company is currently conducting the BACKBEAT global pivotal study in collaboration with Medtronic (NYSE: MDT).
The BDD status provides accelerated FDA engagement and reviews, while potentially supporting higher reimbursement for AVIM-enabled devices through Medicare's New Technology Add-on Payment and Transitional Pass-Through payments programs.
Orchestra BioMed (NASDAQ: OBIO) has reported its full year 2024 financial results, showing a revenue of $2.6 million, down from $2.8 million in 2023. The company's net loss widened to $61.0 million ($1.66 per share) compared to $49.1 million in 2023.
Key financial metrics include cash and marketable securities of $66.8 million as of December 31, 2024. R&D expenses increased to $42.8 million from $33.8 million, primarily due to the BACKBEAT global pivotal study costs. The company raised approximately $30 million through stock sales and credit facility.
Notable developments include continued progress on the BACKBEAT study with Medtronic, submission of a revised design for the Virtue ISR-US pivotal study, and entering mediation with Terumo for partnership restructuring. The company also strengthened its leadership with three new independent directors and appointed Mark Pomeranz as EVP & General Manager of Interventional Therapies.
Orchestra BioMed Holdings (Nasdaq: OBIO) has announced its participation in several upcoming investor conferences in early 2025. The company will present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025, at 2:30 PM ET, and the Barclays 27th Annual Global Healthcare Conference on March 13, 2025, at 8:00 AM ET.
The TD Cowen presentation will be available via webcast, accessible through Orchestra BioMed's website investor section, with replays available for 90 days after the event. Additionally, the company will host one-on-one meetings with investors at the B. Riley Securities Precision Oncology & RadioPharma Conference on February 28, 2025.
Orchestra BioMed Holdings (Nasdaq: OBIO) has appointed Dr. Vivek Reddy as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of its Bioelectronic Therapies Scientific Advisory Board. Dr. Reddy, currently Director of Cardiac Arrhythmia Services at Mount Sinai, will lead the execution of the BACKBEAT global pivotal study, which evaluates the efficacy and safety of atrioventricular interval modulation (AVIM) therapy for patients with uncontrolled hypertension and pacemaker indication.
The AVIM therapy represents a potential always-on, adjustable hypertension treatment that doesn't rely on patient adherence. Dr. Reddy will focus on completing the BACKBEAT study and coordinating efforts among clinical advisors to realize AVIM therapy's potential for hypertension populations with increased cardiovascular risk. The company is also exploring additional therapeutic applications for this technology.
Orchestra BioMed (NASDAQ: OBIO) announced late-breaking data showing favorable effects of atrioventricular interval modulation (AVIM) therapy on diastolic dysfunction in hypertensive patients. The retrospective analysis of the MODERATO II study revealed that AVIM therapy significantly improved echocardiographic markers of diastolic dysfunction, a key factor in heart failure development.
Key findings from the study of 36 patients with sufficient Echo data (61% with diastolic dysfunction) showed that AVIM therapy reduced ambulatory systolic blood pressure by 8.3±9.7 mmHg in treated patients versus 2.2±9.8 mmHg in the control group. Office systolic blood pressure decreased by 12.1±12.8 mmHg in treated patients compared to an increase of 2.9±26.4 mmHg in controls.
The therapy also demonstrated significant improvements in key measures of diastolic function, including increased e' (from 5.9±2.0 to 8.8±3.4cm/sec) and E/A ratio (from 0.86±0.39 to 1.60±0.84), indicating improved left ventricular relaxation and filling.
Orchestra BioMed Holdings (NASDAQ: OBIO) has appointed Christopher Cleary to its Board of Directors as an independent member, effective January 30, 2025. Cleary, former Senior Vice President of Corporate Development at Medtronic, brings over three decades of experience in corporate development, M&A, and R&D collaborations.
During his tenure at Medtronic, Cleary facilitated over 35 acquisitions and orchestrated the $6 billion sale of Covidien Group's medical supply assets to Cardinal Health. He previously served as CEO of Alesia Capital Services and led M&A teams at GE Capital, closing acquisitions totaling more than $60 billion across 200+ transactions globally.
Additionally, Eric A. Rose, M.D. will transition from Board Member to Board Member Emeritus and Strategic Advisor after seven years of service, continuing to provide expertise and guidance to Orchestra BioMed.
Orchestra BioMed (Nasdaq: OBIO) announced two presentations at the 2024 Innovation in Cardiology Intervention (ICI) meeting in Tel Aviv. The presentations focus on the BACKBEAT global pivotal study and AVIM therapy for treating uncontrolled hypertension in patients requiring dual-chamber pacemakers.
Dr. Avi Fischer will present insights on the unmet medical needs of pacemaker patients with uncontrolled hypertension. Dr. Andrea Russo will discuss AVIM therapy's mechanism of action and clinical evidence, including results from the MODERATO I and II pilot studies, demonstrating how the therapy modulates the autonomic nervous system to reduce blood pressure.
Orchestra BioMed Holdings (Nasdaq: OBIO) announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York, NY from December 3-5, 2024. The company's management will deliver a fireside chat presentation on Wednesday, December 4, 2024, at 3:00 PM EST. The presentation will be available via webcast, with a replay accessible on the Orchestra BioMed website's Events section for 90 days afterward. The company will also be available for one-on-one meetings during the conference.
Orchestra BioMed (NASDAQ: OBIO) reported Q3 2024 financial results with revenue of $1.0 million, up from $0.4 million in Q3 2023. The company posted a net loss of $15.4 million ($0.41 per share). Cash position stood at $66.9 million as of September 30, 2024, with an additional $15 million drawn from Hercules Capital facility in November. R&D expenses increased to $11.6 million due to BACKBEAT study costs. The company continues to advance its BACKBEAT global pivotal study with Medtronic and is preparing for Virtue SAB coronary pivotal studies. Operating runway is expected into second half of 2026.